Suven Life Sciences Ltd, a key player in the pharmaceutical sector, reported a significant widening of its consolidated net loss in the fourth quarter of FY25, reaching Rs 43.95 crore, up from Rs 26.54 crore in the previous year’s comparable period. The company’s quarterly revenue fell to Rs 1.47 crore from Rs 2.39 crore, reflecting challenges in both revenue generation and expense management. The full-year results mirrored this trend, with a sharp decline in both revenue and net profit.